Joice Rocha
McGill University
6 Papers
20 Citations
Joice Rocha is an academic researcher from McGill University. The author has contributed to research in topics: Prostate cancer & Docetaxel. The author has an hindex of 5, co-authored 6 publications. Previous affiliations of Joice Rocha include McGill University Health Centre.
Chat about Author
Papers
Electrochemical red-ox therapy of prostate cancer in nude mice.
Fabio Cury,Bimal Bhindi,Joice Rocha,Eleonora Scarlata,Katia El Jurdi,Michel Ladouceur,Stéphane Beauregard,Ashok K. Vijh,Yosh Taguchi,Simone Chevalier +9 more
TL;DR: Electrochemical therapy for prostate cancer was assessed in human PC-3 and LNCaP tumor xenografts growing subcutaneously in nude mice, yielding the longest recurrence-free survival and higher cure rates, especially with 4 Pt-Ir electrodes.
21
Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study
Joice Rocha,Armen Aprikian,Marie Vanhuyse,Fabio Cury,Jason Hu,Noémie Prévost,Alice Dragomir +6 more
- 28 Mar 2017
TL;DR: The effectiveness of abiraterone in older patients who were ineligible for chemotherapy was similar to that of patients with prior docetaxel exposure, and the real-world survival benefits of abIRaterone were similar to those in the COU-AA-301 trial.
12
Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study
Alice Dragomir,Alice Dragomir,Joice Rocha,Joice Rocha,Marie Vanhuyse,Marie Vanhuyse,Fabio Cury,Fabio Cury,Wassim Kassouf,Wassim Kassouf,Jason Hu,Jason Hu,Armen Aprikian,Armen Aprikian +13 more
TL;DR: Patient age seems to be a strong determinant in the of selection mcrpc therapy, affecting the probability of the use of chemotherapy, bone-targeted therapy, or palliative rt, and the availability of enzalutamide since February 2014 will likely produce additional changes in mcrPC management.
8
A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
Jose Joao Mansure,Roland Nassim,Simone Chevalier,Konrad M. Szymanski,Joice Rocha,Saad Aldousari,Wassim Kassouf +6 more
TL;DR: The results suggest that PPARγ agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.